https://www.thebodypro.com/article/switching-to-emtricitabinetenofovir-alafenamide-ft
Emtricitabine/Rilpivirine/Tenofovir Alafenamide (Odefsey)CROI (Conference on Retroviruses and Opportunistic Infections)

Switching to Emtricitabine/Tenofovir Alafenamide (F/TAF) Maintains Viral Suppression With Better Bone and Kidney Safety

    Joel Gallant, M.D., M.P.H., presents 48-week results at CROI 2016.
    Joel Gallant, M.D., M.P.H., presents 48-week results at CROI 2016.